Tissue Heart Valves Market Report 2026

Tissue Heart Valves Market Overview

• Tissue Heart Valves market size has reached to $1.52 billion in 2025 • Expected to grow to $1.72 billion in 2030 at a compound annual growth rate (CAGR) of 2.5% • Growth Driver: Impact Of Increasing Cardiovascular Disease Prevalence On The Growth Of The Market • Market Trend: Next-Generation Avalus Ultra Valve Enhances Surgical Aortic Tissue Valve Procedures • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tissue Heart Valves Market?

Tissue heart valves are heart valves made from biological tissue (rather than mechanical materials) used in heart valve replacement surgeries. They are often used as an alternative to mechanical heart valves and are designed to mimic the function of natural heart valves. The main types of tissue heart valves are stented tissue heart valves and stentless tissue heart valves. Stented tissue heart valves are bioprosthetic valves supported by a metal or polymer frame (stent) to provide structure and facilitate implantation during valve replacement surgeries. They are available in various valve types, including aortic, mitral, tricuspid, and pulmonary valves. Additionally, they are used by several end-users, including hospitals, ambulatory surgical centers, and other end-users.

What Is The Tissue Heart Valves Market Growth Forecast?

The tissue heart valves market size is expected to see steady growth in the next few years. It will grow to $1.72 billion in 2030 at a compound annual growth rate (CAGR) of 2.5%. The growth in the forecast period can be attributed to expansion of TAVR procedures, minimally invasive cardiac surgery growth, longer valve durability innovation, rising healthcare access, cardiology specialization growth. Major trends in the forecast period include preference for bioprosthetic valves, rising transcatheter valve procedures, improved tissue preservation techniques, reduced long-term anticoagulation use, aging population valve replacement demand.

Global Tissue Heart Valves Market Segmentation

1) By Type: Stented Tissue Heart Valves, Stentless Tissue Heart Valves 2) By Procedure Type: Surgical Aortic Valve Replacement (SAVR), Transcatheter Aortic Valve Replacement (TAVR) 3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End-Users Subsegments: 1) By Stented Tissue Heart Valves: Bovine Pericardial Valves, Porcine Valves 2) By Stentless Tissue Heart Valves: Bovine Pericardial Stentless Valves, Homograft Valves

What Is The Driver Of The Tissue Heart Valves Market?

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the tissue heart valves market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders affecting the heart and blood vessels, including conditions such as heart attacks, strokes, and hypertension. The increasing prevalence of cardiovascular diseases (CVDs) is primarily driven by factors such as unhealthy lifestyles, aging populations, increased prevalence of risk factors, poor diets, physical inactivity, smoking, stress, and urbanization, leading to higher rates of heart-related disorders globally. Tissue heart valves are crucial in addressing cardiovascular diseases (CVDs) by providing a biocompatible, durable, and less thrombogenic solution for patients requiring valve replacement, improving long-term heart function, and reducing the risk of complications. For instance, in September 2024, according to a report published by the Heart Failure Society of America (HFSA), a US-based professional organization company, approximately 6.7 million Americans aged 20 and older are currently living with heart failure (HF), with projections indicating this number will increase to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050 respectively. Therefore, the increasing prevalence of cardiovascular diseases drives the growth of the tissue heart valve industry.

Key Players In The Global Tissue Heart Valves Market

Major companies operating in the tissue heart valves market are Abbott Laboratories, Medtronic PLC, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, LifeNet Health Inc., TTK Healthcare Ltd., Braile Biomédica, Anteris Technologies Ltd., Labcor Laboratórios Ltd., CARDION s.r.o., CryoLife Inc., Colibri Heart Valve LLC, Foldax Inc., Balance Medical Technologies Co. Ltd., MiCardia Corporation, St. Jude Medical Inc., Sorin Group, Hancock J & Co.

Global Tissue Heart Valves Market Trends and Insights

Major companies operating in the tissue heart valves market are focusing on developing innovative products, such as surgical aortic tissue valves, to facilitate ease of use at implant and lifetime patient management. A surgical aortic tissue valve is a prosthetic heart valve made from biological tissue, typically used to replace a diseased or damaged aortic valve in heart surgery. For instance, in June 2024, Medtronic plc., an Ireland-based technology company, launched the Avalus Ultra valve, a next-generation surgical aortic tissue valve designed to enhance ease of use during implantation and support long-term patient management. Built on 10 years of clinical experience with the Avalus valve, it features a low valve profile, a polyetheretherketone (PEEK) base frame for consistent circularity and an industry-leading Effective Orifice Area (EOA) for improved blood flow. The valve also includes a radiopaque coil for clear visibility in future valve-in-valve procedures, offering long-term durability for patients with aortic stenosis.

What Are Latest Mergers And Acquisitions In The Tissue Heart Valves Market?

In February 2024, Foldax Inc., a US-based medical device company, partnered with Dolphin Life Science India LLP. The agreement aims to enable in-country manufacturing of the Tria polymer mitral surgical heart valve in India. Dolphin Life Science India LLP is an India-based life sciences company specializing in heart valve manufacturing and distribution.

Regional Outlook

North America was the largest region in the tissue heart valves market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Tissue Heart Valves Market?

The tissue heart valves market consists of sales of porcine xenograft valves, bovine pericardial valves, and autograft valves. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.